Developing a new diagnostic algorithm for human papilloma virus associated oropharyngeal carcinoma: an investigation of HPV DNA assays

• Published in: Journal of otolaryngology 2017-02, Vol.46 (1), p.11-11
• Main Authors: Cohen, Natasha, Gupta, Michael, Doerwald-Munoz, Lilian, Jang, Dan, Young, James Edward Massey, Archibald, Stuart, Jackson, Bernard, Lee, Jenny, Chernesky, Max
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Algorithms; Biopsy, Fine-Needle; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - virology; Cohort Studies; DNA, Viral - analysis; Female; Head and Neck Neoplasms - pathology; Head and Neck Neoplasms - virology; Humans; Immunohistochemistry; Male; Middle Aged; Ontario; Original; Oropharyngeal Neoplasms - pathology; Oropharyngeal Neoplasms - virology; Papillomaviridae - isolation & purification; Papillomavirus Infections - diagnosis; Prognosis; Retrospective Studies; Risk Assessment; ROC Curve; Squamous Cell Carcinoma of Head and Neck
• ISSN: 1916-0216; 1916-0208; 1916-0216
• DOI: 10.1186/s40463-017-0189-z

Human papilloma virus (HPV) has been implicated in the development of a large proportion of oropharyngeal squamous cell carcinoma (OPSCC). Current techniques used to diagnose HPV etiology require histopathologic analysis. We aim to investigate the diagnostic accuracy of a new application non-histopathologic diagnostic tests to help assist diagnosis of HPV-related oropharyngeal tumors. Patients with OPSCC with nodal metastasis were consecutively recruited from a multidisciplinary cancer clinic. Appropriate samples were collected and analyzed. The various tests examined included COBAS® 4800, Cervista® HR and Genotyping. These tests were compared to p16 staining, which was used as the diagnostic standard. StataIC 14.2 was used to perform analysis, including sensitivity, specificity and receiver operator characteristic [ROC] curves. The COBAS® FNA (area under ROC 0.863) and saliva (area under ROC 0.847) samples performed well in diagnosing HPV positive and negative tumors. Samples tested with Cervista® did not corroborate p16 status reliably. We were able to increase the diagnostic yield of the COBAS® FNA samples by applying the results of the saliva test to negative FNA samples which correctly identified 11 additional p16 positive tumors (area under ROC 0.915). Surrogate testing for HPV using alternate methods is feasible and closely predicts the results of standard diagnostic methods. In the future, these could minimize invasive procedures for diagnosing HPV-related oropharyngeal cancer, but also help to diagnose and treat patients with unknown primaries.